Page 334 - Read Online

Page 10 of 10 Yao et al. Hepatoma Res 2018;4:30 I http://dx.doi.org/10.20517/2394-5079.2018.32

2014;14:803-17.
69. Zheng WJ, Yao M, Qian Q, Sai WL, Qiu LW, Yang JL, Wu W, Dong ZZ, Yao DF. Oncogenic secretory clusterin in hepatocellular
carcinoma: Expression at early staging and emerging molecular target. Oncotarget 2017;8:52321-32.
70. Dong ZZ, Zhu XD, Li Z, Mao YG, Chai YL, Yao DF, Sun HC, Zhu JY, Ma KS. Advances in basic and clinical research on hepatocellular
carcinoma in 2016. Zhonghua Gan Zang Bing Za Zhi 2017;25:85-93. (in Chinese)
71. Yang Y, Yao M, Fang M, Zheng WJ, Dong ZZ, Yao DF. Molecular markers for the monitoring of malignant transformation of hepatocytes
and early diagnosis of liver cancer. Zhonghua Gan Zang Bing Za Zhi 2017;25:325-8. (in Chinese)
72. Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, Meng X. Abnormal expressiom of hepatoma specific γ-glutamyl transferase and
alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000;88:761-9.
73. Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL, Chen J. Values of circulating GPC-3 mRNA
and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2013;12:171-9.
74. Erdal H, Gül Utku Ö, Karatay E, Çelik B, Elbeg Ş, Doğan İ. Combination of DKK1 and AFP improves diagnostic accuracy of hepatocellular
carcinoma compared with either marker alone. Turk J Gastroenterol 2016;27:375-81.
75. Guo Y, Wang J, Zhang L, Shen S, Guo R, Yang Y, Chen W, Wang Y, Chen G, Shuai X. Theranostical nanosystem-mediated identification
of an oncogene and highly effective therapy in hepatocellular carcinoma. Hepatology 2016;63:1240-55.
76. Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma cells
with hepatitis B virus. Transl Oncol 2018;11:511-7.
77. Shang S, Hua F, Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget
2017;8:33972-89.
78. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A,
Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P,
Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer
through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A 2013;110:20224-9.
79. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits
c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008;68:1213-20.
80. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin
signaling in mammary epithelial cells. Carcinogenesis 2009;30:331-9.
81. Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt/beta-catenin in colon cancer. Expert Opin Ther Targets 2014;18:611-5.
82. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, Fulciniti M, Munshi NC, Xu W,
Kung AL, Shivdasani RA, Walensky LD, Carrasco DR. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt
signaling. Sci Transl Med 2012;4:148ra117.
83. Yu D, Dong Z, Yao M, Wu W, Yan M, Yan X, Qiu L, Chen J, Sai W, Yao D. Targeted glypican-3 gene transcription inhibited the
proliferation of human hepatoma cells by specific short hairpin RNA.Tumour Biol 2013;34:661-8.
84. Jin Y, Wang J, Han J, Luo D, Sun Z. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1
and Snail2 and suppressing WNT/β-cadherin signaling pathway. Exp Cell Res 2017;360:210-7.
85. Kim SS, Cho HJ, Lee HY, Park JH, Noh CK, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY. Genetic polymorphisms in the
Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular
carcinoma. Clin Biochem 2016;49:792- 801.
86. Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor
effects of sorafenib against hepatocellular carcinoma. Cancer Lett 2016;381:58-66.
87. Shen YN, He HG, Shi Y, Cao J, Yuan JY, Wang ZC, Shi CF, Zhu N, Wei YP, Liu F, Huang JL, Yang GS, Lu JH. Krüppel-like factor 8
promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling. Mol Carcinog 2017;56:751-60.
88. Shibata T, Arai Y, Totoki Y. Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci 2018;109:1282-91.